Melatonin inhibits the proliferation of prostate cancer cells through MT1 receptor-mediated mechanisms including activation of protein kinase A and protein kinase C, inhibition of the NF-κB activation and modulation of androgen receptor signaling [307,308]. Here, AR is linked to prostate carcinoma.